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A B S T R A C T
Mitochondria are the powerhouse organelles present in all eukaryotic cells. They play a fundamental role in cell
respiration, survival and metabolism. Stimulation of G-protein coupled receptors (GPCRs) by dedicated ligands
and consequent activation of the cAMP·PKA pathway ﬁnely couple energy production and metabolism to cell
growth and survival. Compartmentalization of PKA signaling at mitochondria by A-Kinase Anchor Proteins
(AKAPs) ensures eﬃcient transduction of signals generated at the cell membrane to the organelles, controlling
important aspects of mitochondrial biology. Emerging evidence implicates mitochondria as essential bioener-
getic elements of cancer cells that promote and support tumor growth and metastasis. In this context, mi-
tochondria provide the building blocks for cellular organelles, cytoskeleton and membranes, and supply all the
metabolic needs for the expansion and dissemination of actively replicating cancer cells. Functional interference
with mitochondrial activity deeply impacts on cancer cell survival and proliferation. Therefore, mitochondria
represent valuable targets of novel therapeutic approaches for the treatment of cancer patients. Understanding
the biology of mitochondria, uncovering the molecular mechanisms regulating mitochondrial activity an-
dmapping the relevant metabolic and signaling networks operating in cancer cells will undoubtly contribute to
create a molecular platform to be used for the treatment of proliferative disorders.
Here, we will highlight the emerging roles of signaling pathways acting downstream to GPCRs and their
intersection with the ubiquitin proteasome system in the control of mitochondrial activity in diﬀerent aspects of
cancer cell biology.
1. Introduction
Mitochondria are cell autonomous organelles that provide the en-
ergy production and all the metabolic needs for most replicating eu-
karyotic cells. Defective mitochondia have been causally linked to
ageing and neurodegenerative disorders [1]. Recently, it has emerged
that mitochondria signiﬁcantly contribute to development and pro-
gression of a wide array of human cancers. In tumor cells, mitochondria
undergo a profound metabolic switch that supplies suﬃcient energy for
the increased metabolic demands and the building blocks for the as-
sembly of intracellular organelles, cytoskeleton and membranes of
newly derived cancer cells. Inhibiting this metabolic reprogramming
signiﬁcantly impacts on the growth and dissemination of several types
of human cancer [2,3]. Understanding the mechanisms adopted by
actively proliferating cells to sustain their metabolic needs represents a
key aspect in the cancer biology ﬁeld.
In proliferating cells, increased metabolic demands are linked to
enhanced energy production andto a rapid adaption of mitochondria to
increased metabolic needs. The metabolic reprogramming of growing
cells is induced and sustained by signaling events elicited by hormones
and growth factors operating at cell membrane and intracellular orga-
nelles [4]. Emerging evidence points to a pivotal role of compartmen-
talized signaling networks in redirecting and supporting the metabolic
switch occurring in normal proliferating cells and, more importantly, in
rapidly dividing cancer cells. Regulation of signaling events at target
sites eﬃciently and rapidly allows mitochondria to adapt their activity
in response to metabolic demands [5–8]. Protein Kinase A (PKA) con-
trols essential aspects of mitochondrial activities. Thus, activation of
PKA by cAMP generating systems tightly regulates a wide array of
mitochondrial functions, as organelle biogenesis and morphology, gene
expression, metabolism, steroidogenesis and survival [9,10]. In mam-
malian cells, PKA holoenzyme is concentrated atthe membrane,
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cytoskeleton and organelles, including mitochondria, by direct inter-
actions with A-Kinase-Anchor-Proteins (AKAPs). AKAPs are a group of
scaﬀold proteins that assemble signaling enzymes, adaptor molecules
and mRNAs, and create intracellular sites where the signals are kine-
tically and spatially transmitted to downstream target subtsrates, eli-
citing major biological responses [11]. In the last few years, it has been
found that diﬀerent classes of AKAPs locally orchestrate signaling
events at mitochondria. Activation and integration of distinct signal
pathways by AKAPs at mitochondria eﬃciently couple hormone sti-
mulation to mitochondrial activities, supporting metabolism and sur-
vival, and providing an eﬃcient system to rapidly adapt mitochondrial
activity to changes in metabolic demands. For their essential role in
mitochondrial metabolism, AKAPs are currently being considered as
therapeutic targets for proliferative disorders, including cancer
[12–14].
This review will focus on the dynamic connections between com-
partmentalized cAMP signaling and mitochondrial activity, with im-
portant implications in the control of cancer cell growth and metabo-
lism.
2. Compartmentalized cAMP signaling
cAMP represents the prototypic second messenger generated at cell
membrane by GPCR-activated adenylate cyclase. In eukaryotes, the
major cAMP-responsive enzyme is protein kinase A (PKA). PKA is a
tetrameric holoenzyme composed of two regulatory subunits (R) and
two catalytic moieties (C). The binding of cAMP to R dissociates the
holoenzyme and releases the C subunit. Phosphorylation of intracellular
substrates by C subunit controls a wide array of cellular functions,
including respiration and metabolism. The composition and the bio-
chemical properties of the R/C subunits allows the generation of dis-
tinct classes of PKA holenzymes with individual sensitivities to cAMP
and diﬀerential tissues and cellular distributions. In this context, the
rate of PKA activation and the persistence and magnitude of cAMP
signals increase the speciﬁcity and sensitivity of cells to distinct GPCR
activators [15–20]. Another layer of complexity in the cAMP signaling
system is represented by the PKA anchor proteins (AKAPs). AKAPs act
as scaﬀold proteins that bind and target PKA holoenzymes to distinct
intracellular compartments. AKAPs employ a PKA-binding motif that
tethers the R subunit of PKA holoenzyme and a targeting module that
localizes the AKAP/kinase complex to a given organelle, membrane or
cytoskeletal element. By spatially distributing PKA holoenzymes within
the cell, AKAPs eﬃciently control the propagation of cAMP signals from
sites of signal generation to downstream substrates/eﬀectors [21,22].
AKAPs also assemble multienzyme complexes which include not only
PKA holoenzymes, but also components of the cAMP generating sys-
tems (receptors and adenylate cyclase), eﬀectors (PKA and Epac) and
attenuating enzymes, such as cAMP-directed phosphodiesterases (PDEs)
and protein phosphatases (PPs). Moreover, AKAPs complexes include
adaptor molecules, mRNAs and eﬀector enzymes distinct from PKA.The
complexes assembled by AKAPs, namely ‘transduceosomes’, generate
highly specialized intracellular microenvironments where diﬀerent
signaling pathways converge and focus, exerting biological eﬀects in
response to stimulation by hormones, cytokines, neurotransmitters and
growth factors. This signaling apparatus operates in multi-cellular or-
ganisms and evolved as a duplication of ancient linear unicellular sys-
tems, where the stimulation of signaling enzymes and adapter proteins
occurred in a single step within the same intracellular location.
Fig. 1. Mitochondrial AKAPs regulate organelle ac-
tivity. Distinct families of AKAPs have been identiﬁed
at the mitochondrial compartments. AKAPs assemble
multifunctional molecular platforms at the OMM and
within the mitochondrial compartment that include
not only PKA, but also other non-PKA partners.
Phosphorylation of mitochondrial subtsrates by PKA
controls essential aspects of organelle physiology. a.
PKA phosphorylation of components of the re-
spiratory chain positively regulates oxidative ATP
synthesis.b. BAD binds to- and inactivates anti-
apoptotic Bcl-2 homologs, promoting apoptosis.
Phosphorylation and inactivation of BAD at the OMM
by AKAP-anchored PKA prevents BAD/Bcl-2 interac-
tion and inhibits apoptosis. c. Sestrin2 is a stress-in-
duced anti-oxidant gene product that acts as inhibitor
of mTORC1. By targeting sestrin2 to mitochondria,
AKAP1 relieves the inhibitory constrain on mTORC1
and promotes anabolism and tumor cell proliferation.
d. Phosphorylation and inactivation of the pro-ﬁssion
protein Drp1 promotes mitochondrial fusion. e.
Transport of cholesterol from cytosol (cyt) to inter-
membrane space (IMS) is stimulated by PKA-depen-
dent phosphorylation of mitochondrial StAR protein.
Consequent conversion of cholesterol to pregneno-
lone by the mitochondrial sidechain cleavage enzyme
system (P450scc) is required for steroid biosynthesis.
f. Phosphorylation of ChChd3 by SKIP-associated
PKA within the mitochondrial compartment is es-
sential for maintaining mitochondrial cristae in-
tegrity/remodeling.
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Pharmacological or genetic interference with the dynamic assembly of
AKAPs complexes in living organisms profoundly impacts on key phy-
siological processes underlying metabolism, respiration, growth, dif-
ferentiation and development [5,11,23–25].
3. Mitochondrial cAMP signaling: mechanisms and actors
Activation of the PKA pathway controls essential aspects of mi-
tochondrial physiology, including respiration, survival, metabolism,
organelle biogenesis and dynamics. Several mitochondrial AKAPs have
been isolated and functionally characterized [9,10] (Fig. 1). Among
these, AKAP1 represents the prototypic mitochondrial AKAP that is
mechanistically linked to essential aspects of mitochondrial metabolism
and dynamics. AKAP1 binds and targets PKA to the outer mitochondrial
membrane (OMM). AKAP1 mRNA undergoes alternative splicing that
generates diﬀerent variants of AKAP1 which include AKAP121,
AKAP100 and AKAP84. All splice variants share the NH2-terminal core
that incorporates the PKA binding motif, but diverge at their C-ter-
minus. The ﬁrst 30 N-terminal residues (MT domain) of the AKAP1
products mediates the interaction of the proteins with the OMM. Ad-
dition of an hydrophobic 33-residue modiﬁer segment upstream to the
MT domain by alternative splicing generates a protein that is targeted
to the endoplasmic reticulum (ER). The dynamic shift in the localiza-
tion of AKAP1-assembled signaling complexes between ER and mi-
tochodria functionally links the two organelles in control of Ca2+
homeostasis and cell respiration [5,26]. This represents an evolu-
tionary-conserved mechanism that redirects cAMP signaling from one
organelle to another in response to speciﬁc metabolic requirements or
stress conditions. However, the presence of a conserved ER targeting
domain at the N-terminus of AKAP1 has been questioned [27].
Mouse AKAP121 and its human (AKAP149) and Drosophila ortho-
logs (MDI) possess a KH domain located at their C-terminus which
mediates interaction with nuclear-encoded mRNAs [28–30]. AKAP1
binding to mRNA and ribosomes at the OMM promotes eﬃcient
translation and co-import of mitochondrial proteins into the organelles,
with important implications for global protein synthesis and mi-
tochondrial physiology [31–33]. Importantly, AKAP1 complexes in-
clude not only PKA, but also protein tyrosine kinases (Src), phosphatase
(PP1, PTPD1), phosphodiesterases, mRNA and adenylate cyclase. The
transduction unit assembled by AKAP1 supports mitochondrial home-
ostasis, metabolism, respiration and survival [34,35].
A wide number of mitochondrial proteins have been identiﬁed and
functionally characterized as PKA substrates. Thus, in metabolically
active cells, hormone stimulation induces PKA-mediated phosphoryla-
tion of diﬀerent components of the oxidative phosphorylation ma-
chinery (OXPHO). The signaling circuitry activated by AKAP1/PKA
complex at mitochondria favors allosteric regulation of the respiratory
enzymes by newly synthesized ATP moieties, signiﬁcantly impacting on
global respiration, thermogenesis and ATP synthesis. Moreover, growth
factor-induced phosphorylation of mitochondrial proteins by AKAP1-
assembled src tyrosine kinase further contributes to the regulation of
mitochondrial activity, integrating distinct signaling pathways travel-
ling from membrane to the organelles [27].
One role of AKAP1 regulated cAMP signaling in cell survival has
been explored mechanistically. BAD is a BH3 proapoptotic Bcl-2 family
member that interacts with- and inactivates anti-apoptotic Bcl-2
homologs. In the presence of death stimuli, inhibition of Bcl-2 activity
by BAD induces mitochondrial cristae disruption, mitochondrial swel-
ling and release of cytochrome c from the organelles, with consequent
activation of caspases and induction of apoptosis. In contrast, survival
stimuli activate ser/thr protein kinases that promote phosphorylation
and inactivation of BAD, thereby inhibiting cell death. BAD has been
isolated in complex with AKAP1 and PKA. In response tosurvival sig-
nals, AKAP121 selectively enhances cAMP-PKA signaling to mi-
tochondria favouring PKA phosphorylation of BAD at Ser155 and pre-
venting its association with- and inhibition of- the anti-apoptotic Bcl-2
protein [36,37]. This is especially important for cells subjected to stress
conditions or serum deprivation. In proliferating cells, instead, activa-
tion of PKA maygenerate divergent biological responses that favor
apoptosis. Thus, mitochondrial survivin, also named IAP (inhibitor of
apoptosis), interacts with its homolog XIAP and with the co-factor he-
patitis B X-interacting protein (HBXIP). The trimeric complex has strong
cytoprotective eﬀects and inhibits apoptosis. Activation of PKA induces
phosphorylation of cytosolic IAP within the XIAP-interacting domain
(Ser20). IAP phosphorylation prevents the formation of the IAP/XIAP
complex and stimulates cell death. PKA action is counteracted by a pool
of mitochondrial ser/thr-phosphatase (PP2A) that dephosphorylates
IAP and promotes survival. Mutations of IAP at the PKA site stabilize
IAP/XIAP complex and inhibit the apoptotic machinery. This ultimately
contributes to tumor growth and dissemination in vivo [38].
The biological activities mediated by AKAP1 at mitochondria are
modulated by the ubiquitin proteasome system (UPS). Following hy-
poxic insult, the RING E3 ubiquitin ligase Siah2 rapidly accumulates
within cells, leading to ubiquitination and proteolysis of PHD2 (prolyl
hydroxylase), an enzyme that under normoxic conditions negatively
controls the stability of the hypoxia sensor HIF-1α (Hypoxia Inducible
Factor-1α) [39,40]. Removing PHD2, Siah2 increases the levels of HIF-
1α and promotes the HIF1α-dependent transcription of several genes,
as vascular endothelial growth factor (VEGF), tumor growth factor β
(TGFβ) and erythropoietin. These growth factors promote vasculariza-
tion, erythropoiesis and metabolism of ischaemic tissue, preventing
further irreversible tissue damage. An important event that occurs
during hypoxia is the downregulation of mitochondrial activities. This
reduces mitochondrial oxidative stress in the presence of low oxygen
levels. This mechanism requires Siah2-dependent ubiquitination and
proteolysis of AKAP1. Degradation of AKAP1 by the UPS rapidly at-
tenuates the oxidative metabolism, promoting adaptation of cells to
accidental hypoxic conditions [41].
The control of AKAP1 stability by UPS is also important for mi-
tochondrial dynamics. Mitochondria are dynamic organelles that un-
dergo fusion or ﬁssion, changing their shape, number and intracellular
distribution in response to ﬂuctuations in metabolic demands. The re-
modeling of mitochondrial morphology is rapid and, in some circum-
stances, quite dramatic. It is vital for mitochondrial activities under
speciﬁc metabolic needs. The balance between fusion and ﬁssion re-
quires the activity of several factors/regulators that actively participate
in mitochondrial dynamics. AKAP1/PKA complex controls mitochon-
dria dynamics by directly modulating the activity of the dynamin-re-
lated protein 1 (Drp1), a protein that promotes mitochondrial ﬁssion.
Thus, phosphorylation and inactivation of Drp1 by PKA within the
AKAP1 complex promotes elongation of mitochondria and enhances
cellular resistance to apoptotic signals. In contrast, dephosphorylation
of Drp1 by the calcium-activated ser/thr phosphatase, calcineurin (also
known as PP2B), restores Drp1 activity and promotes mitochondrial
ﬁssion and cell death. Similarly, proteolysis of AKAP121 by the hy-
poxia-induced Siah2 pathway removes the inhibitory constraint of PKA
on the Drp1/ﬁssion machinery and leads to mitochondria fragmenta-
tion and cell death [42–45]. This exempliﬁes a regulatory mechanism
operated by the AKAP1/PKA signaling module on mitochondria that
ﬁnely controls dynamic events underlying mitochondrial adaptation to
metabolic or environmental stress.
Other AKAPs have been physically and functionally linked to sev-
eral regulators of mitochondrial physiology, including Rab32, WAVE1,
PAP7 and SKIP. RAB32 is a GTPase Rab family member that controls
mitochondrial dynamics and ER activityby an AKAP-like mechanism
[46–48]. A centrally located 20-residue stretch forms an α-helical
wheel that mediates the interaction of Rab32 with PKA, whereas lipid
modiﬁcation of two C-terminal cysteine residues promotes attachment
of the protein at the interface between themitochondrial and ER
membranes (MAM). Localization of Rab32/PKA complexes at MAM is
important for ER calcium homeostasis, mitochondrial dynamics and
survival. Thus, interfering with Rab32 expression or activity induces
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fragmentation and drastic collapse of mitochondria around the micro-
tubule organizing center (MTOC), impeding movement of the orga-
nelles along the neurites and activating the cell death pathway.
WAVE1 (Wiskott-Aldrich syndrome protein verprolin homologous-
1) is a PKA anchor protein expressed in neurons where itcontrols actin
polymerization and cytoskeletal remodeling [49–51]. In mature neu-
rons, WAVE1 is maintained in its inactive state by direct phosphor-
ylation by Cdk5, a cyclin-dependent kinase family member. Stimulation
of neurons with NMDA (N-MethylD-Aspartate) promotes proteolysis of
the regulatory subunit of CDK5 and de-phosphorylation of WAVE1. De-
phosphorylated, active WAVE1 translocates from actin ﬁlaments to
mitochondria. Bound to mitochondria, WAVE1 induces organelle ﬁs-
sion and traﬃcking along ﬁlopodia, promoting ﬁlopodia outgrowth and
spine morphogenesis, a prerequisite for synaptic activity and plasticity.
The mechanisms regulating localization of WAVE1 to mitochondria
possibly involve interaction with mitochondrial BAD family members.
These nucleate multivalent complexes on mitochondria that include
glucokinase (GK), WAVE1 and other PKA-regulated substrates/eﬀec-
tors. The complexes assembled by BAD on mitochondria act as meta-
bolic sensors for nutrient availability and stress stimuli, optimally in-
tegrating glycolytic machinery and respiration with the organelle
network and apoptotic pathway [52–54].
Peripheral-type benzodiazepine receptor-associated protein (PAP7)
is a mitochondrial AKAP that selectively binds and targets type I PKA
holoenzyme (PKAR1A) to the OMM [55–57]. A macromolecular com-
plex including translocator protein (TSPO), the voltage-dependent
anion chanel (VDAC-1), PAP7 and type I-PKA holoenzyme (PKAR1A)
has been isolated from mitochondria and biochemically characterized.
PAP7 is present in all mammalian tissues and cells, with predominant
expression in steroidogenic tissues, such as testis and adrenal gland.
PAP7 myristoylation is required for OMM binding, where it regulates
cholesterol ﬂux from cytosol to mitochondria. PAP7 favours a PKA-di-
rected phosphorylation and catalytic activation of steroidogenesis acute
regulatory protein (StAR) at mitochondria, leading to cholesterol
transport into the organelles. Interfering with PAP7-mediated cAMP
signaling profoundly aﬀects hormone-induced cholesterol transport
into mitochondria and downregulates steroidogenesis in endocrine
cells. In adrenal tumor cells, PAP7 participates in the PKAR1A-depen-
dent mitogenic signaling, supporting tumorigenesis and hormone-in-
dependent hypercortisolism.
Sphingosine kinase type 1-interacting protein (SKIP, SPHKAP) was
originally identiﬁed as a negative regulator of sphingosine kinase 1
activity [58]. Biochemical analyses unvealed that SKIP operates as a
bona ﬁde AKAP that binds with high aﬃnity the PKAR1A [59]. Mapping
analysis identiﬁed two conserved AKAP amphipathic helical wheel
domains at the C-terminus of the protein that might simultaneously
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Fig. 2. Integration of signaling inputs and metabolic pathways in cancer cells. Aberrant activation of the PI3K/AKT pathway increases the mTOR-dependent anabolic
route, inducing mitochondrial biogenesis and transcriptional repression of SIRT4. By removing the inhibitory constrain of SIRT4 on glutaminase (GLS) and glutamate
dehydrogenase (GDH), mTOR supports α-ketoglutarate production and the TCA cycle. In some cancer types, aberrant conversion of α-ketoglutarate to 2-hydro-
xyglutarate (2-HG) by mutated IDH1/2 induced chromating remodeling and transcription of cancer-associated genes. PI3K/AKT/mTOR pathway also activates the
methylentetrahydrofolate dehydrogenase 2 (MTDHD2)-dependent folate pathway, thereby promoting nucleotide biosynthesis. mTOR upregulates PGC1a-dependent
mitochondrial biogenesis and anabolism. Mitochondrial AKAP1 promotes translation and positively contributes to mTOR-dependent signaling cascade. Activation of
AMP-regulated kinase (AMPK) by ROS stimulates a PGC-1α-dependent antioxidant circuitry that further supports mitochondrial homeostasis and metabolism.
Elevation of ROS levels also inhibits prolyl hydroxylases (PHDs) and leads to accumulation of HIF1. HIF1-depedent upregulation of glycolytic enzymes contributes to
the Warburg's eﬀect.
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interact with two PKAR1A holoenzyme moieties [59]. Localization
studies demonstrated that a signiﬁcant fraction of SKIP/PKAR1A com-
plexes could be present within the mitochondrial compartment [58].
Several mitochondrial interactors of SKIP have been identiﬁed, in-
cluding ChChd3, ChChd6, SAM50, MTX1, and MTX2. ChChd3 (Coiled-
Coil-Helix-Coiled-Coil-Helix Domain Containing 3), a peripheral com-
ponent of the intermembrane space essential for maintaining mi-
tochondrial cristae integrity (see below), has been identiﬁed as direct
substrate of PKA. Phosphorylation of ChChd3 by PKA requires SKIP,
suggesting that mitochondrial SKIP/PKA complexes have relevant
physiological roles in cristae integrity/remodeling and mitochondrial
activities [60].
4. Mitochondrial biogenesis, mitophagy and dynamics in cancer
cells
Cellular mitochondrial content plays a central role in metabolic
adaptation of cells to stress conditions and other changes in the mi-
croenvironment. The number of mitochondria is tightly controlled by
two distinct highly conserved mechanisms: biogenesis and mitophagy.
Both events work in an interconnected and dynamic way to ensure
mitochondrial mass, function and quality control [61,62]. In cancer
cells, both mechanisms are crucial for development and progression of a
malignant tumor lesion [63–65].
Mitochondrial biogenesis is regulated by a wide array of factors and
stimuli. Peroxisome proliferator-activated receptor gamma coactivator
1-alpha (PGC1α) is the master regulator of the transcriptional program
that governs mitochondria biogenesis [66,67] (Fig. 2). PGC1α is rapidly
activated following cellular transformation by a variety of oncogenes,
including c-Myc. In normal proliferating cells, c-Myc activation by
growth factors promotes mitochondrial biogenesis that, in turn, en-
hances respiration, survival and metabolism, contributing to the in-
creased energy demands. This mechanism is overstimulated in cancer
cells bearing oncogenic mutations of c-Myc, leading to massive mi-
tochondrial biogenesis that eﬃciently couples the metabolic needs of
cancer cells to aerobic glycolysis and biosynthetic pathways. Interfering
with the PGC1α-dependent transcriptional program negatively impacts
on cancer growth [68]. Moreover, c-Myc activates the AMPK-related
protein ARK5, which is involved in the maintenance of mitochondrial
energy homeostasis [69]. The transcriptional activity of c-Myc is am-
pliﬁed by transcriptional co-activators, such as AMY 1. AMY 1 is a Myc-
associated protein that has been also found in complex with AKAP1 and
functionally linked to spermatogenesis [70]. A role of AKAP1 on AMY-
dependent regulation of c-Myc has not been addressed. PGC1α tran-
scription and accumulation is induced by the mammalian target of ra-
pamycin (mTOR). By modulating PGC1α levels, mTOR directly controls
mitochondrial biogenesis [66,71]. Additionally, mTOR phosphorylation
inhibits the activity of 4E-binding proteins (4E-BPs), a group of trans-
lational inhibitors that aﬀects the synthesis of nuclear-encoded mi-
tochondrial proteins.
In this context, AKAP1 has been recently identiﬁed as a novel c-Myc
target. A cis-acting element within the AKAP1 gene promoter is re-
quired for c-Myc upregulation of AKAP1 transcription [8]. AKAP1 acts
as a central signaling hub on mitochondria, ﬁnely coupling respiration,
biosynthetic pathways, translation and survival [5,28]. c-Myc-mediated
upregulation of AKAP1 is a molecular signature in a wide array of Myc-
overexpressing human cancers, and AKAP1 levels correlate with the
malignant phenotype and poor survival of cancer patients [8]. Inter-
estingly, AKAP1 positively regulates mTOR. Thus, AKAP1 interacts with
sestrin2, a stress-induced gene product that negatively regulates
mTORC1 pathway.By targeting sestrin-2 on mitochondria, AKAP1 re-
lieves the inhibitory constraint of sestrin2 on the mTOR-dependent
metabolic pathway and enhances the scavenging system on the orga-
nelle, supporting cancer cell growth and survival (Fig. 1 and Fig. 2). As
expected, downregulation of AKAP1 increases oxidative stress, inhibits
mTOR pathway, and aﬀects tumor growth [8]. This signaling circuitry
exempliﬁes a mechanism of regulation of mitochondria biogenesis by a
nuclear oncogene-driven assembly of multi-scaﬀold complexes on the
organelles that controls cancer growth and metabolism.
Mitochondria are removed by mitophagy. This is a highly conserved
mechanism that cells adopt to eliminate damaged or unneeded mi-
tochondria, preventing accumulation of dysfunctional organelles that
would otherwise inhibit respiration, metabolism and survival [72].
This, in part, explains the absence of damaged mitochondria, or mi-
tochondria carrying genome mutations aﬀecting organelle activity, in
cancer cells. Selective pressure induces elimination of damaged mi-
tochondria to preserve the metabolic activities that support cancer cell
growth. At the mechanistic level, depolarization of the mitochondrial
membrane activates PINK1 (PTEN-induced putative kinase 1 PINK1),
which in turn recruits Parkin to the outer mitochondrial membrane.
Ubiquitylation of mitochondrial proteins by Parkin activates the mito-
phagy machinery that incorporates and degrades dysfunctional mi-
tochondria. In addition, PINK1 targeted to mitochondria displaces PKA
from AKAP1, impairing the inhibitory phosphorylation of the kinase on
Drp1 and promoting mitochondrial ﬁssion and mitophagy [43]. Con-
versely, PKA counteracts the eﬀects of Parkin on mitochondria. Thus,
PKA phosphorylation of MIC60 and MIC19, two members of the mi-
tochondrial contact site and cristae organizing system (MICOS) of the
inner mitochondrial membrane, prevents recruitment of Parkin to the
mitochondrial membrane and suppresses organelle clearance [73].
In addition to the PINK1/Parkin pathway, mitophagy is activated by
other regulatory proteins, such as BNIP3, NIX, FUNDC1 and BCL2L13
[72]. The relevance of these pathways in promoting mitophagy in
cancer cells and their role in tumor growth and progression is not well
deﬁned. Several oncogenes, including K-Ras, induce transcription and
accumulation of nuclear factors of the MiTF/TFE family proteins that
control the autophagy machinery and lysosome biogenesis. Interfering
with the clearance of damaged mitochondria in oncogene-induced tu-
mors severely aﬀects respiration, growth and survival, impairing de-
velopment and metastasis of the malignant lesions [74].
Mitochondrial dynamics is emerging as an important parameter of
cancer cell growth. Fission and fusion regulate mitochondria mor-
phology; mitochondriaassumean elongated shape after fusion or a
punctiform pattern after ﬁssion [75,76]. Mitochondrial fusion is di-
rected by two distinct GTPase family proteins, mitofusins and OPA1,
whereas ﬁssion is promoted by the dynamin-related protein 1 (Drp1)
and hFis1. Distinct signaling pathways, including the GPCR-cAMP
pathway, control the activity of the fusion and ﬁssion machinery. It is
worth noting that, in rapidly proliferating cancer cells, mitochondria
often assume a fragmented pattern, suggesting that ﬁssion positively
contributes to their metabolic reprogramming. In support of this model,
preventing mitochondrial ﬁssion by selectively targeting Drp1 expres-
sion or activity inhibits cell transformation induced by several onco-
genes, including K-Ras, and severely inhibits tumor growth in vivo
[75,77]. However, other oncogenes, as c-Myc, induce a gene expression
program that ultimately leads to mitochondrial fusion [78]. This ap-
parently conﬂicting evidence clearly suggests that the mechanisms and
the role of mitochondrial dynamics in cancer cell growth are more
complex than initially postulated and demand further investigation.
5. Mitochondrial metabolism and signaling in cancer cells
Mitochondria integrate signal inputs from extracellular stimuli to
modulate and shape the activity of metabolic enzymes and regulators.
In normal cells, interconnections between glycolysis, oxidative phos-
phorylation, tricarboxylic acid cycle (TCA), beta oxidation of fatty acids
(FAO) and the biosynthesis of nucleotides, amino acids, lipids, and
other mitochondrial bioproducts provide an eﬃcient system to support
survival, growth and diﬀerentiation. Modiﬁcation of this system is
critical forthe development of malignant tumors (Fig. 2). Within the
tumor lesion, the rapidly dividing cancer cells undergo a profound
metabolic reprogramming that primarily involves mitochondria in
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order to support their high energetic requirements [65,79–81].
A major metabolic change in cancer cells is the switch to aerobic
glycolysis, also known as ‘Warburg eﬀect’. This shift allows tumor cells
to ferment glucose even in the presence of oxygen. The net eﬀect of the
metabolic shift is the production of large amounts of lactate, which was
initially considered to result from mitochondrial respiratory defects.
However, no functional alteration or enzymatic defects of components
of the respiratory chain are detectable in cancer cells. Instead, the ac-
tivity of the oxidative phosphorylation machinery is fully retained or
even increased in certain types of cancers [82]. At the molecular level,
upregulation of the glycolytic pathway is supported by HIF-1α, which
accumulates within the tumor lesion as consequence of a hypoxic mi-
croenvironment and reactive oxygen species (ROS)-mediated inhibition
of prolyl hydroxylases (PHDs). The eﬀects of ROS are normally coun-
teracted by the SIRT3-mediated deacetylation and activation of the
scavenging enzymes superoxide dismutase SOD2 and IDH2, and by
induction of anti-oxidant genes [83–86].
Oncogenic mutations of K-Ras, c-Myc, phosphatidylinositol-3(PI3)
kinase, or genetic inactivation of tumor suppressors, as p53 and PTEN
(phosphatase and tensin homolog), promote and sustain the high gly-
colytic rate in cancer cells [87–90]. In particular, K-Ras downregulates
mitochondrial respiration by inhibiting the activity of complex I and
increasing mitochondrial ﬁssion and mitophagy [77,91].
Activation of the PI3K/AKT signaling pathway in cancer cells in-
creases the mTOR-dependent anabolic route and promotes mitochon-
drial biogenesis [92,93]. mTOR also represses the transcription of
SIRT4, leading to increased expression of glutaminase (GLS) and glu-
tamate dehydrogenase (GDH). This enhances theconversion of gluta-
mine to glutamate, and glutamate to α-ketoglutarate (α-KG), which
fuels the TCA cycle. A signiﬁcant amount of α-ketoglutarate can be
converted to isocitrate by the isocitrate dehydrogenases (IDHs) to sus-
tain biosynthetic and redox reactions [94,95]. PI3K/AKT/mTOR
pathway also stimulates nucleotide synthesis by upregulating the ex-
pression of methylentetrahydrofolate dehydrogenase 2 (MTDHD2), the
rate-limiting enzyme of the folate pathway [96].
In malignant tumors, activation of AMP-regulated kinase (AMPK),
an enzyme activated under nutrient limitation, confers a metabolic
advantage to rapidly proliferating cells. Within the tumor context,
AMPK promotes mitochondria biogenesis, favours energy production
and metabolism, and facilitates elimination of damaged mitochondria
(mitophagy) that might otherwise negatively aﬀect cancer cell growth
[97,98]. Interestingly, AKAP1 has been identiﬁed as a direct target of
AMPK; AKAP1phosphorylation by AMPK during increased energy de-
mands stimulates respiration and mitochondrial activity [99]. Thus, as
an upstream regulator of mTOR pathway, AKAP1 works at the
boundary between the energy sensing/producing system andthe ana-
bolic pathway [8]. This loop may inﬂuence mechanisms governing
mitochondrial plasticity duringthe course of tumorigenesis, favouring
the metabolic switch in cancer cells. Functional interference with mi-
tochondrial activity in the presence of activated oncogenic pathways
inhibits the growth and metastatic potential of tumor cells. This sup-
ports the concept that metabolic adaptation of mitochondria is a fun-
damental mechanism to support and sustain tumor growth and wide-
spread dissemination of cancer cells.
6. ROS production and oncometabolites
Reactive oxygen species (ROS) are important byproducts of mi-
tochondrial respiration. Although they have been considered as toxic,
their role as second intracellular messengers has been recently docu-
mented. The physiological production of mitochondrial ROS is coun-
terbalanced by a regulated antioxidant system, represented by super-
oxide dismutases (SOD1/2), glutathione, thioredoxin and
peroxiredoxins [100–102]. In cancer cells, ROS accumulation may have
dual functions, as drivers of oncogenic mutations, and as cytotoxic
agents. This is especially relevant under stress or hypoxic conditions,
where ROS levels dramatically increase, stabilizing HIF1-alpha and
supporting survival and mitogenic pathways of cancer cells (Fig. 2). As
example, ROS-mediated oxidation of the active site of PTEN, a negative
regulator of PI3K-AKT pathway, decreases phosphatase activity and
leads to overstimulation of the anabolic pathway and cell survival. Si-
milarly, ROS-mediated inactivation of the tyrosine phosphatase PTP1B,
a negative regulator of most tyrosine kinase receptors (RTKs), sustains
the mitogenic pathways induced by growth factors [103]. Moreover,
ROS-induced oxidation of Src tyrosine kinase at its catalytic cysteine
site promotes and supports metastatic dissemination of cancers [104].
Interestingly, stimulation of ROS synthesis can also intersect AMPK-
dependent metabolic pathways. Thus, ROS activation of AMPK stimu-
lates a PGC-1α-dependent antioxidant circuitry that supports mi-
tochondrial homeostasis and cellular metabolism. Interfering with this
control system in cancer cells leads to accumulation of HIF-1α and to a
metabolic reprogramming [105–108]. Stress conditions and hypoxic
microenvironment can also aﬀect the mitochondrial membrane per-
meability transition (MMPT), causing defects of the apoptotic pathway
and giving rise to tumor cell populations that escape programmed cell
death. The most common example is the overexpression of BCL2 in
many malignant lesions that enhances the resistance of tumor cells to
apoptosis [109]. These ﬁndings suggest that tumor cells can balance
pro-oxidant and anti-oxidant systems that favours accumulation of ROS
to levels adequate to support tumor cell proliferation and metabolic
activities, and to prevent cytotoxic eﬀects and apoptosis.
In addition to ROS, tumor cells accumulate several mitochondrial
metabolites that directly contribute to diﬀerent aspects of tumor cell
biology. Thus, activating mutations of the isocitrate dehydrogenase
enzymes (IDH1/2), in gliomas and in other human cancers, leads to
accumulation of the α-ketoglutarate-derived oncometabolite 2-hydro-
xyglutarate (2-HG) [110] (Fig. 2). This by-product interferes with the
activity of chromatin remodeling enzymes (TET and JHDM), exerting
major eﬀects on gene expression [111,112]. These compounds also
inhibit prolyl hydroxylases (PHD) and stabilize HIF-1α, enhancing the
HIF-1α-induced Warburg eﬀect [113,114]. In some human tumors,
inactivating mutations of the trycarboxylic acid cycle (TCA) enzymes
succinate dehydrogenase (SDH) and fumarate hydratase (FH) lead to
accumulation of two intermediates, fumarate and succinate. High levels
of fumarate also lead to increased cysteine succinylation and con-
sequent inhibition of the Kelch-like ECH-associated protein 1 (KEAP1),
a negative regulator of Nrf2 [115,116]. By removing the inhibitory
constraint of KEAP1, fumarate enhances the Nrf2-mediated anti-oxi-
dant response pathway that supports cell proliferation and tumor
growth.
7. Targeting mitochondria in cancer therapy
The cellular energy production required for anabolic and catabolic
reactions in cancer cells primarily relies within mitochondria.
Mitochondria are also the principal source of reactive oxygene species
(ROS) production that contributes to cancer cell growth and metastasis.
However, high levels of ROS often result in tumor cell death.
Accordingly, excessive enhancing of ROS production can be a valuable
tool to kill cancer cells (Fig. 3). Thus, treatment with 2-methox-
yestradiol (2-ME), with the microtubule-disrupting agent (CYT997) or
with metformin increases ROS levels and promotes tumor cell apoptosis
[117,118]. However, in some cancers, the apoptotic machinery is de-
fective due to overexpression of anti-apoptotic proteins (Bcl-2 or IAP
family members) or to suppression of pro-apoptotic proteins, as BAX
and BAK. Furthermore, tumor cells can develop resistance to treatment
based on the induction of apoptosis. For these reasons, novel strategies
have been developed to target members of the apoptotic machinery. In
particular, Venetoclax, an inhibitor of Bcl-2, or small molecules mi-
micking the function of the IAP inhibitor Smac/Diablo have been used
in clinical trials of cancer patients [119,120].
Mitochondrial metabolism is fundamental for tumor growth, and
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mutations of metabolic enzymes, as IDH1 and IDH2, have been causally
linked to the development and progression of gliomas and leukemia.
Accordingly, selectiveinhibitors of mutated IDH1/2 have been devel-
oped and are currently being used as chemotherapeutics in clinical
trials (Fig. 3). Similarly, chemical interference with the glycolytic
pathway, with OMM permeability or with respiratory chain activitymay
open novel therapeutic windows [121–123].
Targeting compartmentalized cAMP signaling is becoming of in-
terest in translational medicine and several approaches have been
tested and experimentally validated. As an example, peptides spanning
the amphipathic helical wheel of AKAPs have been successfully em-
ployed to delocalize and inhibit cAMP-dependent events at a given
target organelle, both in cell cultures and in vivo, oﬀering potential
applications for disease treatment [124–129]. However, the high con-
servation of the amphipathic helical wheel among diﬀerent families of
AKAPs may generate oﬀ-target eﬀects of the displacing peptides, thus
limiting its clinical value. As an alternative approach, we envisage the
design of competitor molecules targeting unique domains of AKAPs that
are employed in tethering relevant interactors and/or regulators of the
scaﬀold complex. In particular, AKAP1 binds and targets PTPD1/src
complex to mitochondria, which promotes oxidative phosphorylation.
AKAP1 also binds and inhibits sestrin2, a physiological inhibitor of
mTOR pathway. By inhibiting sestrin2, AKAP1 positively regulates the
anabolic pathway [8]. Accordingly, peptides or molecules targeting the
sestrin2 or PTPD1 interaction domains could interfere with mitochon-
drial respiration and anabolism in cancer cells. Moreover, strategies
aimed to delocalize an entire AKAP complex, e.g., the AKAP1 complex
from the mitochondrial compartment, could be even more eﬃcient in
inhibiting oncogenic pathways and metabolic activities, ultimately
leading to cancer cell death (Fig. 3). This approach has been experi-
mentally tested to induce oxidative stress and apoptosis in cardio-
myocytes, both in cell cultures and in vivo [130]. An alternative strategy
to modulate AKAP-regulated oncogenic pathways is to downregulate
AKAP expression. The use of small RNA molecules (siRNAs and
miRNAs) targeting speciﬁc regions of AKAP mRNAs can be employed to
inhibit the growth and progression of AKAP-addicted cancers. Proof-of
principle of the validity of this strategy has been recently provided in an
orthotopic mouse model of human glioblastoma [8,131]. However, the
stability, the biodistribution and the delivery of small RNAs to target
tumor tissues, and possible unacceptable side eﬀects in disrupting of
AKAP complexes, represent a major limitation for these treatments.
8. Concluding remarks
Mitochondria are essential organelles for eukaryotic cells. They are
the sites at which cell respiration, survival signals and metabolic
pathways converge and integrate. In the last decade, the role of mi-
tochondria in signal transduction in addition to their role in cell re-
spiration and metabolism has come to be recognized. A wide array of
signaling relays, adapter proteins, receptors, chanels, transcription
factors and regulators have been isolated from, and are part of the
mitochondrial compartment. Mitochondria now unambiguosly appear
as a cellular hub where metabolism and respiration integrate with
signaling pathways that support cell growth and survival. This is
especially relevant for the development and progression of cancers.
Tumor cells undergo a profound metabolic reprogramming that ulti-
mately provides all the energetic needs to fuel a wide variety of cellular
activities and to support the production of the building blocks for ra-
pidly proliferating cancer cells. Mutations of mitochondrial metabolic
enzymes have been mechanistically linked to the development and
progression of several types of human cancers. For these reasons, mi-
tochondrial metabolism represents a valuable target for novel, more
eﬃcient therapeutic strategies for cancer treatment. The identiﬁcation
of compartmentalized signaling platforms assembled by AKAPs at mi-
tochondria and involved in critical aspects of metabolism and survival,
oﬀers the possibility to design novel tools able to interrupt the trophic
signals by oncogenic pathways that are directed to mitochondria.
Mitochondrial AKAPs may, thus, constitute the Achille's heel of che-
moresistant cancers. Interfering with signaling events regulated by
AKAPs, and preventing signal-induced metabolic switch at mitochon-
dria, will likely provide novel valuable targets for cancer therapy.
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